

	Month (%)	Quarter (%)	FYTD (%)	1 Year (%)	2 Years (% p.a.)	3 Years (% p.a.)	5 Years (% p.a.)	7 Years (% p.a.)	10 Years (% p.a.)	Since Inception ^ (% p.a.)
Perennial Value Australian Shares Trust (Net)	-1.2	2.2	7.8	6.3	4.2	7.5	7.9	6.7	6.5	9.1
S&P/ASX 300 Accumulation Index	-2.9	1.2	10.0	9.0	5.5	7.1	8.0	8.0	7.8	8.1
<b>Value Added</b>	<b>1.7</b>	<b>1.0</b>	<b>-2.2</b>	<b>-2.7</b>	<b>-1.3</b>	<b>0.4</b>	<b>-0.1</b>	<b>-1.3</b>	<b>-1.3</b>	<b>1.0</b>

^Since inception: March 2000. Past performance is not a reliable indicator of future performance.

## Overview

The global risk rally which began in November, ran into a wall in April. While markets had been ignoring rising bond yields for some time, higher than expected inflation readings caused the market to sharply reassess the prospects for near term rate cuts. At the same time, economic data, which had been remarkably resilient, also came in a little softer than expected.

This saw markets correct globally, with most major markets falling over the month. In the US, the S&P500 declined -2.6%, while the NASDAQ fell -2.4%. The Nikkei 225, which had been the star performer over the last 12 months, lost -6.0%. On the positive, the FTSE100 gained +2.4% to a new record high. The Shanghai Composite, which had been the only market to deliver a negative return over the last 12 months, also gained +2.4%. Sentiment towards China has been very negative in recent times, and some glimmers of positive news saw some money move back towards the region.

The Australian market was also weak, with the ASX300 Accumulation Index falling -2.9% over the month, to register its first decline in 6 months. The changing view on the outlook for interest rates saw REITs (-8.4%) the worst performing sector, giving back some of its recent rally. Consumer Discretionary (-6.0%) also fell as shadows of doubt crept in around the consensus soft landing view. Most other sectors also delivered negative returns. Metals & Mining (+1.3%) outperformed, with generally stronger commodity prices and improved China sentiment.

## Fund Characteristics

The Trust aims to grow the value of your investment over the long term via a combination of capital growth and income, by investing in a diversified portfolio of Australian shares, and to provide a total return (after fees) that exceeds the S&P/ASX 300 Accumulation Index measured on a rolling three-year basis.

### Portfolio Managers

Stephen Bruce, Andrew King

### Trust FUM

AUD \$472 million

### Distribution Frequency

Half yearly

### Minimum Initial Investment

\$25,000

### Trust Inception Date

March 2000

### Fees

0.92% p.a.

### APIR Code


IOF0200AU

Portfolio Characteristics - FY25	Trust	Market
Price to Earnings (x)	15.3	16.2
Price to Free Cash Flow (x)	12.6	13.9
Gross Yield (%)	5.3	5.1
Price to NTA (x)	2.2	2.5

Source: Perennial Value Management. As at 30 April 2024


The above figures are forecasts only. While due care has been used in the preparation of forecast information, actual outcomes may vary in a materially positive or negative manner.

## Growth of \$100,000 Since Inception




Performance shown net of fees with distributions reinvested. Does not take into account any taxes payable by an investor. Past performance is not a reliable indication of future performance.

## Top 5 Over / Underweight Positions vs Index



## Sector Active Exposure vs Index



## Trust Review

The Trust returned -1.2%, after-fees in April, outperforming the benchmark by +1.7%.

Key contributors to performance over the month included the Trust's gold miners. The gold price has been very strong in recent times, setting new highs despite rising bond yields and reduced expectations of interest rate cuts. This could potentially be explained by increased central bank buying by certain countries as geopolitical tensions escalate. At the stock specific level, Newmont (+20.6%) rallied sharply after delivering a strong first quarter result, with higher production and lower costs. Northern Star (+4.1%) also outperformed.

Base metals continued to recover, with copper, aluminium, zinc, manganese and nickel, all up strongly over the month. In terms of commodity prices, supply is just as important as demand, and in many commodities, supply is tight. Copper is a good case in point, seeing significant downgrades to global production forecasts. The sum of these cuts is expected to move the market from surplus into deficit this year. This has driven the copper price to well over US\$4/lb, seeing our holding in pure-play copper miner, Sandfire Resources (8.3%), continue to perform well, while diversified base metals producer, South32 (+17.0%) performed very strongly. There were also some signs of life in the pricing of lithium and rare earths, which drove outperformance by Lynas Corporation (+13.0%) and Pilbara Resources (+3.4%) respectively.

The iron ore price also rose modestly, continuing to prove far more resilient than many had expected, seeing Rio Tinto (+7.6%) and Fortescue Metals (-0.1%) also outperform. BHP (-2.9%) was softer, after announcing a takeover offer for Anglo American. This transaction would significantly increase BHP's exposure to copper, which is likely to see strong long-term demand growth, driven by electrification and the energy transition. By contrast, demand for iron ore, the current driver of the business may well slow over the coming years.

Resmed (+8.1%) outperformed as it continues to recover after being sold off on the back of concerns around the potential impact of GLP-1 weight loss drugs on demand for its sleep apnea devices. During the month, the results of a key clinical study were released showing the impact of these weight loss drugs on sleep apnea. As expected, as people lost weight, their sleep apnea improved. However, they were generally still at a severity where ongoing CPAP therapy would be recommended by a doctor. In our view, this risk is exaggerated as, while the "slimming down" of the population will no doubt have some effect of the incidence of sleep apnea, weight is only one risk factor. For example, age is another key risk factor and populations continue to age globally. More generally, sleep apnea is an under-diagnosed condition, with a large unaddressed market.

The sell-off on the back of these concerns was the perfect example of when from time to time, you get the opportunity invest in a very high-quality business when it is trading at a significant discount to its historical relative valuation. In the case of Resmed, we have made over +30% on our investment as the stock has been re-rated towards its historical levels. As a result, we have recently been taking profits as their valuation discount has narrowed.

The Trust also benefitted from its underweight position in the REITs and consumer facing stocks, which retreated as yields rose and hopes of rate cuts receded.

Also in the Healthcare sector, there were very strong performances from Telix (+20.3%) and Immutep (+17.1%). Telix is experiencing very strong growth in sales of Illucix, its prostate cancer imaging agent. This is gaining significant market share due the logistical benefits to hospitals from its ease of preparation compared to alternative products. The company also has a solid pipeline of new products under development. Immutep rallied after reporting positive trial data for the immunotherapy drug it is developing for use in conjunction with Merck's blockbuster oncology drug, KEYTRUDA. These stocks have significant upside potential from here.

The main detractors from performance over the month were packaging company, Orora (-19.1%), as investors continue to be concerned about their recent French acquisition. While there are many red flags around the deal, in our view, these have now been largely factored into the share price. Other underperformers included Aristocrat Leisure (-7.6%) and Ramsay Healthcare (-7.1%).

## Trust Activity

During the month, we exited the majority of our holding in Virgin Money UK, believing that there was unlikely to be a competing bid or an increase in the price of the current takeover offer. A number of other holdings were trimmed to take profits such as Goodman Group and Northern Star. At month end, stock numbers were 62 and cash was 2.2%.

## Outlook

Globally, inflation continues to moderate, albeit at a slowing pace, as while goods inflation has fallen sharply, services inflation is proving more persistent. While the expected timing of interest rate cuts has been pushed out, the consensus view is that rate cuts are coming, and a soft landing will be achieved.

This would be an excellent outcome. However, history suggests that soft landings are few and far between, so a degree of caution is warranted. Should inflation prove resurgent, then the sentiment could change quickly. Given that much of the market – particularly the Tech sector – is very fully-valued, there is not much margin for error here.


Similarly, the Australian economy continues to look reasonably healthy, boosted by immigration, however, GDP growth is weakening, and per capita GDP growth is negative. While the prospect of RBA interest rate cuts is positive for sentiment and the upcoming tax cuts will also boost disposable income, there are signs the labour market is beginning to soften, leaving us cautious on the consumer.

Despite the Chinese economic woes, demand for most commodities remains healthy and supply is generally constrained. We continue to believe that Resources represent the clear Value opportunity in the market at the present time.

While there is a high level of economic uncertainty, our focus remains on investing in quality companies with proven business models and strong balance sheets, which are offering attractive valuations and have the ability to deliver high levels of franked dividend income to investors.

**Invest Online Now**

## Contact us

 Level 27, 88 Phillip Street  
Sydney NSW 2000

 1300 730 032

 [invest@perennial.net.au](mailto:invest@perennial.net.au)

 [www.perennial.net.au](http://www.perennial.net.au)

Signatory of:



Issued by Perennial Value Management Limited (ABN 22 090 879 904, AFSL No. 247293) as the Investment Manager. The Responsible Entity is Perennial Investment Management Limited (ABN 13 108 747 637, AFSL No. 275101). Perennial Partners Limited (ABN 90 612 829 160) is a Corporate Authorised Representative (1293138) of Perennial Value Management Limited. Both the Investment Manager and Responsible Entity form part of Perennial Partners. This promotional statement is provided for information purposes only. Accordingly, reliance should not be placed on this promotional statement as the basis for making an investment, financial or other decision. This promotional statement does not take into account your investment objectives, particular needs or financial situation and is not intended to constitute advertising or advice of any kind and you should not construe the contents of promotional statement as legal, tax, investment or other advice. This promotional statement does not constitute an offer or inducement to engage in an investment activity nor does it form part of any offer documentation, offer or invitation to purchase, sell or subscribe for interests in any type of investment product or service. You should read and consider any relevant offer documentation applicable to any investment product or service and consider obtaining professional investment advice tailored to your specific circumstances before making any investment decision. While every effort has been made to ensure the information in this promotional statement is accurate, its accuracy, reliability or completeness is not guaranteed. Past performance is not a reliable indicator of future performance. Gross performance does not include any applicable management fees or expenses. Net performance is based on redemption price for the period and assumes that all distributions are reinvested. Fees indicated reflect the maximum applicable. Contractual arrangements, including any applicable management fee, may be negotiated with certain large investors. Investments in the Trusts must be accompanied by an application form. The current relevant product disclosure statements, additional information booklet, application forms and target market determination can be found on Perennial's website [www.perennial.net.au](http://www.perennial.net.au). Use of the information on our website is governed by Australian law and is subject to the terms of use. No distribution of this material will be made in any jurisdiction where such distribution is not authorised or is unlawful.